FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
FDA Approves Alectinib for Early-Stage ALK+ NSCLC
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Clipping of Lymph Nodes May Aid Axillary Surgery in Breast Cancer
In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.
Nanatinostat Combo Yields Responses in R/R EBV+ Peripheral T-Cell Lymphoma
Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.